"Retina Vitreous surgeons/physicians serving San Jose, Mountain View, San Mateo, Daly City and Monterey. Specializing in the research and treatment of Macular Degeneration, Diabetic Retinopathy, and other retinal disease."

During the past decade, Northern California Retina Vitreous Associates conducted 52 clinical trials. In the 10-year time frame, 52 clinical trials started and 24 clinical trials were completed, i.e. on average, 46.2% percent of trials that started reached the finish line to date. In the past 5 years, 24 clinical trials started and 19 clinical trials were completed. i.e. 79.2% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Northern California Retina Vitreous Associates" #1 sponsor was "Hoffmann-La Roche" with 12 trials, followed by "Clearside Biomedical, Inc." with 7 trials sponsored, "Genentech, Inc." with 5 trials sponsored, "Kodiak Sciences Inc" with 5 trials sponsored and "Northern California Retina Vitreous Associates" with 5 trials sponsored. Other sponsors include 23 different institutions and companies that sponsored additional 27 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Northern California Retina Vitreous Associates" #1 collaborator was "National Eye Institute (NEI)" with 4 trials as a collaborator, "Allergan" with 3 trials as a collaborator, "Genentech, Inc." with 3 trials as a collaborator, "Duke University" with 2 trials as a collaborator and "National Institutes of Health (NIH)" with 2 trials as a collaborator. Other collaborators include 6 different institutions and companies that were collaborators in the rest 14 trials.

According to Clinical.Site data, the most researched conditions in "Northern California Retina Vitreous Associates" are "Diabetic Macular Edema" (12 trials), "Geographic Atrophy" (10 trials), "Macular Degeneration" (5 trials), "Age-Related Macular Degeneration" (4 trials) and "Macular Edema" (4 trials). Many other conditions were trialed in "Northern California Retina Vitreous Associates" in a lesser frequency.

Most popular intervention types in "Northern California Retina Vitreous Associates" are "Drug" (53 trials), "Other" (14 trials), "Procedure" (5 trials), "Biological" (3 trials) and "Device" (3 trials). Other intervention types were less common.

The name of intervention was led by "Sham Procedure" (12 trials), "Aflibercept" (8 trials), "Faricimab" (6 trials), "KSI-301" (5 trials) and "Ranibizumab" (4 trials). Other intervention names were less common.

The vast majority of trials in "Northern California Retina Vitreous Associates" are 62 trials for "All" genders.

Currently, there are NaN active trials in "Northern California Retina Vitreous Associates". undefined are not yet recruiting, 5 are recruiting, 12 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 32 completed trials in Northern California Retina Vitreous Associates, undefined suspended trials, and 11 terminated clinical trials to date.

Out of the total trials that were conducted in Northern California Retina Vitreous Associates, 7 "Phase 1" clinical trials were conducted, 25 "Phase 2" clinical trials and 26 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 2 trials, and there were also 2 trials that are defined as “Not Applicable".

Northern California Retina Vitreous Associates has several departments that took part in Clinical trials: "Retina Vitreous Associates Medical Group Inc" - 2 trials